Shoreline Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Shoreline Biosciences's estimated annual revenue is currently $17.5M per year.
- Shoreline Biosciences's estimated revenue per employee is $155,000
- Shoreline Biosciences's total funding is $186M.
Employee Data
- Shoreline Biosciences has 113 Employees.
- Shoreline Biosciences grew their employee count by 23% last year.
Shoreline Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder, CSO | Reveal Email/Phone |
2 | Co-Founder, Chairman & CEO | Reveal Email/Phone |
3 | Co-Founder | Reveal Email/Phone |
4 | CFO | Reveal Email/Phone |
5 | VP, Clinical Operations | Reveal Email/Phone |
6 | VP, People and Culture | Reveal Email/Phone |
7 | VP & Controller | Reveal Email/Phone |
8 | VP Research | Reveal Email/Phone |
9 | VP, Alliance and Project Management | Reveal Email/Phone |
10 | VP, Smart Manufacturing | Reveal Email/Phone |
Shoreline Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Shoreline Biosciences?
Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.
keywords:N/A
$186M
Total Funding
113
Number of Employees
$17.5M
Revenue (est)
23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Shoreline Biosciences News
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells...
Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells.
SHORELINE BIOSCIENCES ANNOUNCES ORAL PRESENTATION on ipsc-derived NK cell (iNK) platform AT INNATE KILLER SUMMIT meeting 2022.
SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapie ...
Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biotechnology co ...
Other Companies in La Jolla
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.5M | 114 | 12% | N/A |
#2 | $15.6M | 120 | -69% | $401.5M |
#3 | $20M | 133 | 7% | N/A |
#4 | $28.8M | 137 | -69% | N/A |
#5 | $21.2M | 137 | 19% | $224M |